Ranking of transarterial and targeted therapies for advanced hepatocellular carcinoma in the era of immuno-oncology: A network meta-analysis of randomized sorafenib-controlled trials
GastroenterologiaSobre o estudo
- Desenho
- Revisão sistemática
- Nível de evidência
- 1 · Evidência consolidada
- Revista
- Hepatology communications
- Publicado em
- 4 jul 2022
- Citações
- 3
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
Ranking of transarterial and targeted therapies for advanced hepatocellular carcinoma in the era of immuno-oncology: A network meta-analysis of randomized sorafenib-controlled trials
Jihyun An, Seungbong Han, Ha Il Kim, Ju Hyun Shim
Descritores MeSH
- Carcinoma, Hepatocellular
- Antineoplastic Agents
- Liver Neoplasms
- Chemoembolization, Therapeutic
- Phenylurea Compounds
- Quinolines
- Randomized Controlled Trials as Topic
- Humans
- Sorafenib
- Combined Modality Therapy
Veja também
Estudos relacionados
- Combined treatments based on interventional therapy improve the prognosis of patients with HCC: an umbrella review of systematic reviews and meta-analyses
- AGA Clinical Practice Guideline on Systemic Therapy for Hepatocellular Carcinoma
- Phase I-IV Drug Trials on Hepatocellular Carcinoma in Asian Populations: A Systematic Review of Ten Years of Studies
- Clinical efficacy of lenvatinib, trans-arterial chemoembolization, and PD-1/L1 inhibitors in advanced hepatocellular carcinoma: a systematic review and network meta-analysis